BD said its new patient comfort clinical studies surrounding its recently launched Physioject equipment shows less pain when self-injecting.
The device encompasses a pre-filled syringe with a hidden-needle. It is intended for patients suffering from chronic diseases like rheumatoid arthritis, and MS.
Patients using the Physioject scored an average of 6 on the pain scale, instead of 15 – the average for a normal pre-filled syringe.
However when asked the reason for reduced pain, Joel Cotten, European product manager of pharmaceutical systems, said the team could only guess it is psychosomatic.
He added: “The device is a non-medical device, appears more friendly, all the needles are not visible. We can guess this helps to create better comfort. Very frankly, we don’t know exactly why, but we are currently conducting more studies.”
On the eve of the historical vote on Scottish independence from the UK tomorrow, we take a...
Who's in, who's out: all the latest changes in senior pharmaceutical appointments.
Plus senior hires at Merck Serono, Astellas, the European Medicines Agency, and more.
Our People on the Move column tracks pharma's movers and shakers.
Our weekly round-up of the bright young things and big cheeses in pharmaceuticals.